Ovarian cancer is often diagnosed late with high mortality rates, prompting a need for deeper genetic profiling beyond BRCA1 and BRCA2 mutations to find additional diagnostic and therapeutic targets.
The study analyzed 27 genes in 50 ovarian cancer patients using next-generation sequencing, identifying mutations particularly in BRCA1, CDK4, MSH2, and PTEN, with some unique to the Pakistani cohort.
Functional analyses demonstrated that these mutations led to reduced expression of the respective proteins and positional biomarkers, while Resveratrol was predicted as a potential therapeutic agent through molecular docking studies.